Clinical Trial Update: UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating interleukin-2 with radiotherapy and pembrolizumab in patients refractory to checkpoint blockade; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Proleukin (aldesleukin)

Snippet

Sponsor: Megan Daly, MD | Conditions: Non Small Cell Lung Cancer, Metastatic Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-29